Pyxis Oncology prioritizes PYX-201 after 50% ORR in HNSCC; suspends PYX-106

Pyxis Oncology, Inc.

Confirmed 50% ORR and 100% DCR in 6 heavily pretreated HNSCC patients in Phase 1 of PYX-201.
Across 6 solid tumor types (n=31), PYX-201 achieved 26% ORR with dose-dependent responses in taxane-pretreated patients.
PYX-106 program suspended; Phase 1 monotherapy enrolled 45 patients, was safe and well-tolerated.
Current cash position expected to fund PYX-201 monotherapy and combination trials into 2H 2026.
Monotherapy and pembrolizumab combination trials for PYX-201 expected to start dosing in early 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.